Bacterial Conjunctivitis
27
1
1
20
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
18 trials with published results (67%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
7.4%
2 terminated out of 27 trials
90.9%
+4.4% vs benchmark
67%
18 trials in Phase 3/4
90%
18 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (27)
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers
AL-15469A for the Treatment of Bacterial Conjunctivitis
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis